Organogenesis says PREPARE RCT shows PuraPlyAM boosts 12-week closure rates in hard-to-heal diabetic foot ulcers
ORGO•Organogenesis said a peer-reviewed publication of previously released PREPARE trial results showed better 12-week wound closure outcomes with PuraPlyAM than with standard care alone. The study met its primary endpoint.
1. Trial results published
Organogenesis reported the peer-reviewed publication of previously released results from its PREPARE randomized trial of PuraPlyAM in hard-to-heal diabetic foot ulcers. The study met its primary endpoint, showing better wound closure outcomes at 12 weeks versus standard care alone.
